Harvard Bioscience (HBIO)
Harvard Bioscience on one page: short interest, daily short volume, fails to deliver, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as laboratory analytical instruments.
45K
Short interest
settlement 2026-09-30
2.6
Days to cover
unchanged vs prior
50.4%
Short share of volume
2026-10-12
837
Fails to deliver
settlement 2026-08-06
Thu 5 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-10-12.
Short interest
FINRA, twice a month. The newest 24 settlements in the table, 48 in the chart. JSONAs of 30 September 2026, short interest in HBIO is 44,996 shares, down 3,534 shares over the last month. Over the last 48 readings it ranged from 44,996 shares (30 September 2026) to 7,047,412 shares (31 October 2025). The latest reading sits at the bottom of that range. At the reported average volume of 17K shares a day that is 2.6 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/hbio" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-09-30 | 44,996 | -6.5% | 17,224 | 2.61 |
| 2026-09-15 | 48,146 | -0.8% | 18,572 | 2.59 |
| 2026-08-31 | 48,530 | -17.5% | 22,038 | 2.20 |
| 2026-08-14 | 58,827 | -4.1% | 22,249 | 2.64 |
| 2026-07-31 | 61,370 | +9.6% | 11,587 | 5.30 |
| 2026-07-15 | 56,015 | -21.0% | 12,909 | 4.34 |
| 2026-06-30 | 70,890 | -20.6% | 16,660 | 4.26 |
| 2026-06-15 | 89,250 | -16.0% | 26,043 | 3.43 |
| 2026-05-29 | 106,197 | -12.2% | 28,345 | 3.75 |
| 2026-05-15 | 120,933 | -29.2% | 36,133 | 3.35 |
| 2026-04-30 | 170,730 | -29.9% | 41,190 | 4.14 |
| 2026-04-15 | 243,452 | +187.2% | 98,327 | 2.48 |
| 2026-03-31 | 84,759 | -82.1% | 63,170 | 1.34 |
| 2026-03-13 | 473,057 | +4.3% | 450,644 | 1.05 |
| 2026-02-27 | 453,726 | -32.3% | 252,937 | 1.79 |
| 2026-02-13 | 670,309 | +14.6% | 753,726 | 1.00 |
| 2026-01-30 | 585,089 | +34.6% | 295,407 | 1.98 |
| 2026-01-15 | 434,784 | -2.4% | 319,711 | 1.36 |
| 2025-12-31 | 445,314 | -24.1% | 565,892 | 1.00 |
| 2025-12-15 | 586,355 | +22.8% | 679,967 | 1.00 |
| 2025-11-28 | 477,324 | -65.3% | 1,308,583 | 1.00 |
| 2025-11-14 | 1,377,735 | -80.5% | 3,070,070 | 1.00 |
| 2025-10-31 | 7,047,412 | +1115.3% | 28,457,097 | 1.00 |
| 2025-10-15 | 579,892 | -14.9% | 589,504 | 1.00 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 12 October 2026, the short share of HBIO volume is 50.4%, up 27.6 points over the last five sessions. Over the last 30 readings it ranged from 5.5% (14 September 2026) to 74.9% (3 September 2026). The latest reading is 16.4 points above the 30-session average of 34.0%, on 5K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-12 | 3K | 5K | 50.4% | 0 |
| 2026-10-09 | 913 | 3K | 26.2% | 0 |
| 2026-10-08 | 2K | 5K | 38.0% | 0 |
| 2026-10-07 | 2K | 5K | 42.0% | 0 |
| 2026-10-06 | 533 | 6K | 9.5% | 0 |
| 2026-10-05 | 3K | 11K | 22.8% | 0 |
| 2026-10-02 | 2K | 6K | 27.6% | 0 |
| 2026-10-01 | 10K | 28K | 35.8% | 0 |
| 2026-09-30 | 2K | 5K | 50.1% | 0 |
| 2026-09-29 | 4K | 19K | 18.8% | 0 |
| 2026-09-28 | 6K | 22K | 27.2% | 1 |
| 2026-09-25 | 526 | 3K | 17.3% | 0 |
| 2026-09-24 | 2K | 11K | 21.5% | 0 |
| 2026-09-23 | 6K | 15K | 43.9% | 0 |
| 2026-09-22 | 2K | 5K | 39.9% | 0 |
| 2026-09-21 | 3K | 11K | 28.7% | 1,443 |
| 2026-09-18 | 5K | 11K | 47.4% | 0 |
| 2026-09-17 | 3K | 5K | 54.1% | 0 |
| 2026-09-16 | 2K | 4K | 56.7% | 0 |
| 2026-09-15 | 768 | 7K | 11.4% | 0 |
| 2026-09-14 | 2K | 32K | 5.5% | 0 |
| 2026-09-11 | 898 | 4K | 23.5% | 0 |
| 2026-09-10 | 6K | 10K | 56.8% | 0 |
| 2026-09-09 | 754 | 7K | 10.3% | 0 |
| 2026-09-08 | 3K | 6K | 54.5% | 0 |
| 2026-09-04 | 2K | 4K | 35.3% | 0 |
| 2026-09-03 | 7K | 9K | 74.9% | 0 |
| 2026-09-02 | 7K | 17K | 41.2% | 0 |
| 2026-09-01 | 2K | 11K | 16.8% | 0 |
| 2026-08-31 | 5K | 16K | 31.3% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 6 August 2026, the fails-to-deliver balance in HBIO is 837 shares, up 739 shares over the last settlement date. Over the last 30 readings it ranged from 3 shares (11 February 2026) to 107,498 shares (16 January 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-08-06 | 837 | $6.37 | $5K |
| 2026-07-02 | 98 | $6.05 | $593 |
| 2026-05-21 | 359 | $5.40 | $2K |
| 2026-04-24 | 1,951 | $6.78 | $13K |
| 2026-04-22 | 2,265 | $6.56 | $15K |
| 2026-04-13 | 2,308 | $4.31 | $10K |
| 2026-04-09 | 4 | $5.55 | $22 |
| 2026-04-08 | 4 | $5.40 | $22 |
| 2026-04-07 | 4 | $5.53 | $22 |
| 2026-04-06 | 4 | $5.20 | $21 |
| 2026-04-02 | 4 | $5.09 | $20 |
| 2026-04-01 | 4 | $4.87 | $19 |
| 2026-03-31 | 4 | $4.66 | $19 |
| 2026-03-30 | 4 | $4.87 | $19 |
| 2026-03-27 | 4 | $5.07 | $20 |
| 2026-03-26 | 4 | $5.13 | $21 |
| 2026-03-25 | 4 | $5.13 | $21 |
| 2026-03-24 | 4 | $5.34 | $21 |
| 2026-03-23 | 234 | $5.27 | $1K |
| 2026-03-20 | 8 | $5.60 | $45 |
| 2026-03-19 | 4 | $4.88 | $20 |
| 2026-03-18 | 6 | $4.87 | $29 |
| 2026-03-17 | 2,244 | $5.01 | $11K |
| 2026-02-11 | 3 | $0.60 | $2 |
| 2026-01-27 | 873 | $0.58 | $506 |
| 2026-01-16 | 107,498 | $0.58 | $62K |
| 2026-01-15 | 10,923 | $0.57 | $6K |
| 2026-01-14 | 7,013 | $0.59 | $4K |
| 2026-01-13 | 2,296 | $0.62 | $1K |
| 2025-12-26 | 5,307 | $0.73 | $4K |
Insider trades
SEC Form 4, newest first, 50 of 100 shown. JSONNo open-market insider trades were reported for HBIO in the last 90 days. The most recent filings are listed below. Latest filing: Eade Katherine A. (Director) on 2026-06-09.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-06-09 | Eade Katherine A. | Director | Grant | 17K | $0.00 | $0 | 59K |
| 2026-06-09 | Snider William | Director | Grant | 17K | $0.00 | $0 | 49K |
| 2026-06-09 | Gagnon Robert E. | Director | Grant | 17K | $0.00 | $0 | 28K |
| 2026-06-09 | DENELSKY STEPHEN J | Director | Grant | 17K | $0.00 | $0 | 38K |
| 2026-06-09 | Benson Seth Benjamin | Director | Grant | 17K | $0.00 | $0 | 28K |
| 2026-03-20 | Duke John D | Chief Executive Officer | Grant | 75K | $0.00 | $0 | 180K |
| 2026-03-20 | Frost Mark T | Chief Financial Officer | Grant | 30K | $0.00 | $0 | 48K |
| 2026-03-17 | Snider William | Director | Buy | 8K | $4.85 | $41K | 32K |
| 2026-03-17 | DENELSKY STEPHEN J | Director | Buy | 10K | $4.87 | $49K | 21K |
| 2026-03-16 | Duke John D | Chief Executive Officer | Buy | 5K | $5.01 | $25K | 105K |
| 2026-03-16 | Snider William | Director | Buy | 13K | $4.99 | $62K | 24K |
| 2026-03-16 | Frost Mark T | Chief Financial Officer | Buy | 5K | $5.00 | $25K | 18K |
| 2025-12-17 | Snider William | Director | Grant | 110K | $0.00 | $0 | 110K |
| 2025-09-05 | DENELSKY STEPHEN J | Director | Grant | 110K | $0.00 | $0 | 110K |
| 2025-08-15 | Green James W | Director | Disposition | 113K | $0.00 | $0 | 2.5M |
| 2025-08-15 | Green James W | Director | Disposition | 66K | $0.00 | $0 | 2.6M |
| 2025-08-15 | Green James W | Director | Tax withholding | 12K | $0.53 | $6K | 2.6M |
| 2025-08-15 | Green James W | Director | Disposition | 119K | $0.00 | $0 | 2.6M |
| 2025-08-15 | Green James W | Director | Tax withholding | 33K | $0.53 | $18K | 2.8M |
| 2025-08-15 | Green James W | Director | Disposition | 49K | $0.00 | $0 | 2.8M |
| 2025-08-08 | Duke John D | Chief Executive Officer | Grant | 500K | $0.00 | $0 | 1.0M |
| 2025-08-08 | Duke John D | Chief Executive Officer | Grant | 500K | $0.00 | $0 | 500K |
| 2025-07-16 | Gagnon Robert E. | Director | Grant | 110K | $0.00 | $0 | 110K |
| 2025-07-16 | Eade Katherine A. | Director | Grant | 110K | $0.00 | $0 | 421K |
| 2025-07-16 | Benson Seth Benjamin | Director | Grant | 110K | $0.00 | $0 | 110K |
| 2025-05-12 | Frost Mark T | Interim CFO | Grant | 100K | $0.00 | $0 | 125K |
| 2025-03-19 | Green James W | Chief Executive Officer | Tax withholding | 38K | $0.69 | $27K | 2.8M |
| 2025-03-19 | Cote Jennifer | Chief Financial Officer | Tax withholding | 6K | $0.69 | $4K | 159K |
| 2024-12-31 | Green James W | Chief Executive Officer | Disposition | 145K | $0.00 | $0 | 2.9M |
| 2024-12-29 | Cote Jennifer | Chief Financial Officer | Tax withholding | 5K | $1.98 | $9K | 164K |
| 2024-12-29 | Cote Jennifer | Chief Financial Officer | Tax withholding | 4K | $1.98 | $8K | 160K |
| 2024-12-29 | Green James W | Chief Executive Officer | Tax withholding | 25K | $1.98 | $50K | 3.0M |
| 2024-12-29 | Green James W | Chief Executive Officer | Tax withholding | 57K | $1.98 | $113K | 3.1M |
| 2024-06-13 | Green James W | Chief Executive Officer | Buy | 10K | $2.91 | $29K | 3.1M |
| 2024-06-06 | Green James W | Chief Executive Officer | Buy | 20K | $3.07 | $61K | 3.1M |
| 2024-05-21 | EDRICK ALAN I | Director | Grant | 46K | $0.00 | $0 | 274K |
| 2024-05-21 | Eade Katherine A. | Director | Grant | 46K | $0.00 | $0 | 311K |
| 2024-05-21 | Loewald Thomas W | Director | Grant | 46K | $0.00 | $0 | 295K |
| 2024-05-21 | LOY BERTRAND | Director | Grant | 57K | $0.00 | $0 | 57K |
| 2024-03-06 | Cote Jennifer | Chief Financial Officer | Tax withholding | 10K | $4.11 | $41K | 169K |
| 2024-03-05 | Cote Jennifer | Chief Financial Officer | Grant | 36K | $0.00 | $0 | 143K |
| 2024-03-05 | Green James W | Chief Executive Officer | Grant | 215K | $0.00 | $0 | 2.9M |
| 2024-03-05 | Green James W | Chief Executive Officer | Grant | 215K | $0.00 | $0 | 3.1M |
| 2024-03-05 | Cote Jennifer | Chief Financial Officer | Grant | 36K | $0.00 | $0 | 179K |
| 2023-12-31 | Green James W | Chief Executive Officer | Tax withholding | 83K | $5.35 | $443K | 2.7M |
| 2023-12-29 | Cote Jennifer | Chief Financial Officer | Tax withholding | 3K | $5.35 | $18K | 110K |
| 2023-12-29 | Cote Jennifer | Chief Financial Officer | Tax withholding | 3K | $5.35 | $14K | 107K |
| 2023-12-29 | Green James W | Chief Executive Officer | Tax withholding | 52K | $5.35 | $279K | 2.7M |
| 2023-12-29 | Green James W | Chief Executive Officer | Tax withholding | 24K | $5.35 | $129K | 2.8M |
| 2023-12-29 | Green James W | Chief Executive Officer | Tax withholding | 29K | $5.35 | $154K | 2.8M |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON4 holders report 5% or more of HBIO in their latest filing, 3 on Schedule 13D (active intent). The largest reported stake is William Snider at 16.0% of the class (846,000 shares), filed 2026-03-23 for an event on 2025-12-17.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-09-22 | 13G/Ano. 8 | Leviticus Partners LPinvestment adviser | 235K | 5.2% | 2026-09-14 |
| 2026-03-23 | 13D | William Sniderindividual | 846K | 16.0% | 2025-12-17 |
| 2026-03-23 | 13D | BroadOak Capital Partners, LLCparent holding company | 825K | 15.6% | 2025-12-17 |
| 2026-03-23 | 13D | BroadOak Income Fund, L.P.partnership | 810K | 15.3% | 2025-12-17 |
| 2026-03-23 | 13D | BroadOak Fund VI, L.P.partnership | 15K | 0.3% | 2025-12-17 |
13F holders
Tracked managers holding HBIO at their latest 13F. JSON4 of the 30 tracked managers held HBIO at their latest 13F, $1.6M in total at quarter-end prices. Two Sigma Investments is the largest at $704K (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Two Sigma Investments | 2026-06-30 | 115K | $704K | 0.00% | +428 |
| Renaissance Technologies | 2026-06-30 | 99K | $611K | 0.00% | -2K |
| Millennium Management | 2026-06-30 | 33K | $201K | 0.00% | -14K |
| Citadel Advisors | 2026-06-30 | 13K | $81K | 0.00% | new |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Harvard Bioscience in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Harvard Bioscience (HBIO), SEC CIK 1123494, listed on Nasdaq, classified by the SEC as laboratory analytical instruments. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-09-30.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-12.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-08-06.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-09-22.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-11.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-06-09.JSON and CSV
- Company record
- EDGAR filing index for CIK 1123494Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as laboratory analytical instruments
Other company pages
Datasets
Frequently Asked Questions
How much of HBIO is sold short?
What is HBIO's daily short volume?
Does HBIO have fails to deliver?
Are HBIO insiders buying or selling?
Who owns 5% or more of HBIO?
Which tracked 13F managers own HBIO?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.